Login to Your Account

Lumateperone un-pawsed as dog data satisfy agency; Intra-Cellular trial goes on

By Randy Osborne
Staff Writer

Wednesday, August 23, 2017

Intra-Cellular Therapies Inc. vice president Kimberly Vanover told BioWorld that the company "should have everything we need" to file an NDA for lumateperone, also known as ITI-007, in the middle of next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription